Cargando…

Comparative analysis of target gene exon sequencing by cognitive technology using a next generation sequencing platform in patients with lung cancer

Next generation sequencing (NGS) technology is an increasingly important clinical tool for therapeutic decision-making. However, interpretation of NGS data presents challenges at the point of care, due to limitations in understanding the clinical importance of gene variants and efficiently translati...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu, Yan, Wenqing, Xie, Zhi, Guo, Weibang, Lu, Danxia, Lv, Zhiyi, Zhang, Xuchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783722/
https://www.ncbi.nlm.nih.gov/pubmed/33414916
http://dx.doi.org/10.3892/mco.2020.2198
_version_ 1783632166714867712
author Chen, Yu
Yan, Wenqing
Xie, Zhi
Guo, Weibang
Lu, Danxia
Lv, Zhiyi
Zhang, Xuchao
author_facet Chen, Yu
Yan, Wenqing
Xie, Zhi
Guo, Weibang
Lu, Danxia
Lv, Zhiyi
Zhang, Xuchao
author_sort Chen, Yu
collection PubMed
description Next generation sequencing (NGS) technology is an increasingly important clinical tool for therapeutic decision-making. However, interpretation of NGS data presents challenges at the point of care, due to limitations in understanding the clinical importance of gene variants and efficiently translating results into actionable information for the clinician. The present study compared two approaches for annotating and reporting actionable genes and gene mutations from tumor samples: The traditional approach of manual curation, annotation and reporting using an experienced molecular tumor bioinformationist; and a cloud-based cognitive technology, with the goal to detect gene mutations of potential significance in Chinese patients with lung cancer. Data from 285 gene-targeted exon sequencing previously conducted on 115 patient tissue samples between 2014 and 2016 and subsequently manually annotated and evaluated by the Guangdong Lung Cancer Institute (GLCI) research team were analyzed by the Watson for Genomics (WfG) cognitive genomics technology. A comparative analysis of the annotation results of the two methods was conducted to identify quantitative and qualitative differences in the mutations generated. The complete congruence rate of annotation results between WfG analysis and the GLCI bioinformatician was 43.48%. In 65 (56.52%) samples, WfG analysis identified and interpreted, on average, 1.54 more mutation sites in each sample than the manual GLCI review. These mutation sites were located on 27 genes, including EP300, ARID1A, STK11 and DNMT3A. Mutations in the EP300 gene were most prevalent, and present in 30.77% samples. The Tumor Mutation Burden (TMB) interpreted by WfG analysis (1.82) was significantly higher than the TMB (0.73) interpreted by GLCI review. Compared with manual curation by a bioinformatician, WfG analysis provided comprehensive insights and additional genetic alterations to inform clinical therapeutic strategies for patients with lung cancer. These findings suggest the valuable role of cognitive computing to increase efficiency in the comprehensive detection and interpretation of genetic alterations which may inform opportunities for targeted cancer therapies.
format Online
Article
Text
id pubmed-7783722
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-77837222021-01-06 Comparative analysis of target gene exon sequencing by cognitive technology using a next generation sequencing platform in patients with lung cancer Chen, Yu Yan, Wenqing Xie, Zhi Guo, Weibang Lu, Danxia Lv, Zhiyi Zhang, Xuchao Mol Clin Oncol Articles Next generation sequencing (NGS) technology is an increasingly important clinical tool for therapeutic decision-making. However, interpretation of NGS data presents challenges at the point of care, due to limitations in understanding the clinical importance of gene variants and efficiently translating results into actionable information for the clinician. The present study compared two approaches for annotating and reporting actionable genes and gene mutations from tumor samples: The traditional approach of manual curation, annotation and reporting using an experienced molecular tumor bioinformationist; and a cloud-based cognitive technology, with the goal to detect gene mutations of potential significance in Chinese patients with lung cancer. Data from 285 gene-targeted exon sequencing previously conducted on 115 patient tissue samples between 2014 and 2016 and subsequently manually annotated and evaluated by the Guangdong Lung Cancer Institute (GLCI) research team were analyzed by the Watson for Genomics (WfG) cognitive genomics technology. A comparative analysis of the annotation results of the two methods was conducted to identify quantitative and qualitative differences in the mutations generated. The complete congruence rate of annotation results between WfG analysis and the GLCI bioinformatician was 43.48%. In 65 (56.52%) samples, WfG analysis identified and interpreted, on average, 1.54 more mutation sites in each sample than the manual GLCI review. These mutation sites were located on 27 genes, including EP300, ARID1A, STK11 and DNMT3A. Mutations in the EP300 gene were most prevalent, and present in 30.77% samples. The Tumor Mutation Burden (TMB) interpreted by WfG analysis (1.82) was significantly higher than the TMB (0.73) interpreted by GLCI review. Compared with manual curation by a bioinformatician, WfG analysis provided comprehensive insights and additional genetic alterations to inform clinical therapeutic strategies for patients with lung cancer. These findings suggest the valuable role of cognitive computing to increase efficiency in the comprehensive detection and interpretation of genetic alterations which may inform opportunities for targeted cancer therapies. D.A. Spandidos 2021-02 2020-12-24 /pmc/articles/PMC7783722/ /pubmed/33414916 http://dx.doi.org/10.3892/mco.2020.2198 Text en Copyright: © Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Chen, Yu
Yan, Wenqing
Xie, Zhi
Guo, Weibang
Lu, Danxia
Lv, Zhiyi
Zhang, Xuchao
Comparative analysis of target gene exon sequencing by cognitive technology using a next generation sequencing platform in patients with lung cancer
title Comparative analysis of target gene exon sequencing by cognitive technology using a next generation sequencing platform in patients with lung cancer
title_full Comparative analysis of target gene exon sequencing by cognitive technology using a next generation sequencing platform in patients with lung cancer
title_fullStr Comparative analysis of target gene exon sequencing by cognitive technology using a next generation sequencing platform in patients with lung cancer
title_full_unstemmed Comparative analysis of target gene exon sequencing by cognitive technology using a next generation sequencing platform in patients with lung cancer
title_short Comparative analysis of target gene exon sequencing by cognitive technology using a next generation sequencing platform in patients with lung cancer
title_sort comparative analysis of target gene exon sequencing by cognitive technology using a next generation sequencing platform in patients with lung cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783722/
https://www.ncbi.nlm.nih.gov/pubmed/33414916
http://dx.doi.org/10.3892/mco.2020.2198
work_keys_str_mv AT chenyu comparativeanalysisoftargetgeneexonsequencingbycognitivetechnologyusinganextgenerationsequencingplatforminpatientswithlungcancer
AT yanwenqing comparativeanalysisoftargetgeneexonsequencingbycognitivetechnologyusinganextgenerationsequencingplatforminpatientswithlungcancer
AT xiezhi comparativeanalysisoftargetgeneexonsequencingbycognitivetechnologyusinganextgenerationsequencingplatforminpatientswithlungcancer
AT guoweibang comparativeanalysisoftargetgeneexonsequencingbycognitivetechnologyusinganextgenerationsequencingplatforminpatientswithlungcancer
AT ludanxia comparativeanalysisoftargetgeneexonsequencingbycognitivetechnologyusinganextgenerationsequencingplatforminpatientswithlungcancer
AT lvzhiyi comparativeanalysisoftargetgeneexonsequencingbycognitivetechnologyusinganextgenerationsequencingplatforminpatientswithlungcancer
AT zhangxuchao comparativeanalysisoftargetgeneexonsequencingbycognitivetechnologyusinganextgenerationsequencingplatforminpatientswithlungcancer